Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Behzad Etemad

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|August 10, 2019
Learning From the Exceptions: HIV Remission in Post-treatment ControllersBehzad Etemad, Elmira Esmaeilzadeh, Jonathan Z Li
The American Journal of Tropical Medicine and Hygiene|February 14, 2006
Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypesSaima Khanam, Behzad Etemad, Navin Khanna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrinBehzad Etemad, Oscar A Gonzalez, Sean McDonough, et al.
Journal of Virological Methods|February 15, 2015
Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristicsBehzad Etemad, Melissa Ghulam-Smith, Oscar Gonzalez, et al.
The Journal of Infectious Diseases|March 8, 2012
Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infectionManish Sagar, Hisashi Akiyama, Behzad Etemad, et al.
Journal of Virology|July 24, 2009
Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infectionBehzad Etemad, Angela Fellows, Brenda Kwambana, et al.
The American Journal of Tropical Medicine and Hygiene|September 12, 2008
An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypesBehzad Etemad, Gaurav Batra, Rajendra Raut, et al.
AIDS (London, England)|February 26, 2021
Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutationYijia Li, Behzad Etemad, Ruth Dele-Oni, et al.
Retrovirology|November 29, 2014
Characterization of HIV-1 envelopes in acutely and chronically infected injection drug usersBehzad Etemad, Oscar A Gonzalez, Laura White, et al.
Elife|May 21, 2016
Detection and manipulation of live antigen-expressing cells using conditionally stable nanobodiesJonathan Cy Tang, Eugene Drokhlyansky, Behzad Etemad, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|August 10, 2019
Learning From the Exceptions: HIV Remission in Post-treatment ControllersBehzad Etemad, Elmira Esmaeilzadeh, Jonathan Z Li
The American Journal of Tropical Medicine and Hygiene|February 14, 2006
Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypesSaima Khanam, Behzad Etemad, Navin Khanna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrinBehzad Etemad, Oscar A Gonzalez, Sean McDonough, et al.
Journal of Virological Methods|February 15, 2015
Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristicsBehzad Etemad, Melissa Ghulam-Smith, Oscar Gonzalez, et al.
The Journal of Infectious Diseases|March 8, 2012
Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infectionManish Sagar, Hisashi Akiyama, Behzad Etemad, et al.
Journal of Virology|July 24, 2009
Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infectionBehzad Etemad, Angela Fellows, Brenda Kwambana, et al.
The American Journal of Tropical Medicine and Hygiene|September 12, 2008
An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypesBehzad Etemad, Gaurav Batra, Rajendra Raut, et al.
AIDS (London, England)|February 26, 2021
Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutationYijia Li, Behzad Etemad, Ruth Dele-Oni, et al.
Retrovirology|November 29, 2014
Characterization of HIV-1 envelopes in acutely and chronically infected injection drug usersBehzad Etemad, Oscar A Gonzalez, Laura White, et al.
Elife|May 21, 2016
Detection and manipulation of live antigen-expressing cells using conditionally stable nanobodiesJonathan Cy Tang, Eugene Drokhlyansky, Behzad Etemad, et al.
Pageof 3